Analysis of causes for liver function deterioration in patients with HIV/HCV co-infection.

Hepatobiliary Pancreat Dis Int

Department of Infectious Diseases, You'an Hospital, Beijing 100054, China.

Published: November 2004

Background: Co-infection of hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) is common in hemophiliacs and drug abusers. To assess the interaction between HIV and HCV disease progression, we examined 82 HIV/HCV co-infection patients and 62 HCV infection patients.

Methods: Liver function, pathological changes, infection duration, immune function and qualitative HCV-RNA and HCV antibody were compared retrospectively between the two groups of patients.

Results: Fourty-eight patients (58.5%) in the HIV/HCV co-infection group and 53 patients (85.5%) in the HCV infection group showed abnormal liver function. No significant difference was observed in inflammation and fibrosis in the two groups (P=0.187, 0.954). However, liver abnormality in the patients with HIV/HCV co-infection appeared 8 years earlier than in those with HCV infection alone (P<0.001). As to immune function, the counts of CD+4 T and CD+8 T in the HIV/HCV group were (226.35+/-173.49)X10(6)/L and (914.40+/-448.28)X10(6)/L, whereas in the HCV group they were (752.31+/-251.69)X10(6)/L and (529.01+/-170.67)X10(6)/L respectively. The difference in the two groups was highly significant (P<0.001; P<0.001). The ratio of the number of people with both HCV-RNA and HCV antibody positive to the number of HCV-RNA positive and HCV antibody negative in the HIV/HCV group was 52:9, whereas in the HCV group it was 44:1 (P=0.043).

Conclusion: HIV/HCV co-infection can accelerate deterioration of hepatitis C, which may be due to the effect of HIV on cellular immunity and humoral immunity of the body.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hiv/hcv co-infection
16
liver function
12
hcv infection
12
patients hiv/hcv
8
hcv
6
patients
5
co-infection
5
analysis liver
4
function
4
function deterioration
4

Similar Publications

Characterization of Incident Hepatitis C Virus Infection among People Living with HIV in a HIV Clinic in Korea.

Infect Chemother

December 2024

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Medical Center, Seoul, Korea.

Background: Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can cause more rapid progression to cirrhosis than HCV-monoinfection. In this study, incident HCV case (IHCV)s were investigated in a HIV clinic in Korea.

Materials And Methods: A retrospective HIV cohort was constructed who visited National Medical Center in Korea from 2013 to 2022 and performed ≥ 1 anti-HCV antibody tests (anti-HCV) during the study period.

View Article and Find Full Text PDF

Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.

Front Immunol

January 2025

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.

Article Synopsis
  • This study investigated the link between immune checkpoint proteins and liver stiffness in HIV/HCV-coinfected individuals one year after successful HCV treatment, focusing on plasma levels of these proteins and their correlation with liver stiffness measured five years later.
  • 39 patients with advanced liver disease who achieved sustained virologic response (SVR) were analyzed, revealing that although liver stiffness decreased over time, it remained persistently high in 61.5% of participants five years after treatment.
  • Elevated levels of immune checkpoints BTLA, PD-1, and TIM-3 were associated with this persistently high liver stiffness, indicating a potential ongoing immunological impact on liver health even after HCV eradication.
View Article and Find Full Text PDF

Depression is common among people living with HCV and HIV, which contributes to health services utilization (HSU). It is unknown whether successful HCV treatment affects this. We examined depressive symptoms and HSU in people co-infected with HIV-HCV and their association with sustained virologic response (SVR) during the direct-acting antiviral era.

View Article and Find Full Text PDF

Aim Of The Study: To assess the real-life efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in HIV/HCV- positive patients treated with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF).

Material And Methods: Patients were evaluated in terms of their baseline biochemical characteristics, which included platelet count, serum creatinine and bilirubin levels, alanine transaminase (ALT) activity, international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) score.The efficacy endpoint was the achievement of a sustained virologic response at posttreatment week 12 (SVR12), defined as undetectable HCV RNA 12 weeks after the scheduled end of therapy.

View Article and Find Full Text PDF

Background: Hepatitis C virus (HCV) infects nearly one-fourth of people with HIV (PWH). The role of direct-acting antivirals (DAAs) on immune activation in PWH and HCV is poorly understood.

Methods: We quantified plasma HCV RNA and CXCL10 in persons with HCV mono- versus HIV/HCV co-infection receiving Sofosbuvir-Velpatasvir.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!